Thermo Fisher Scientific Inc. TMO
We take great care to ensure that the data presented and summarized in this overview for THERMO FISHER SCIENTIFIC INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TMO
View all-
Vanguard Group Inc Valley Forge, PA33.1MShares$19.7 Billion0.39% of portfolio
-
Black Rock Inc. New York, NY29MShares$17.3 Billion0.4% of portfolio
-
State Street Corp Boston, MA16.6MShares$9.87 Billion0.44% of portfolio
-
Capital World Investors Los Angeles, CA13.5MShares$8.03 Billion1.34% of portfolio
-
Morgan Stanley New York, NY11.8MShares$7 Billion0.56% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.1MShares$5.99 Billion0.72% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.11MShares$4.83 Billion1.1% of portfolio
-
Geode Capital Management, LLC Boston, MA7.5MShares$4.46 Billion0.41% of portfolio
-
Bank Of America Corp Charlotte, NC5.09MShares$3.03 Billion0.28% of portfolio
-
Jpmorgan Chase & CO New York, NY4.42MShares$2.63 Billion0.23% of portfolio
Latest Institutional Activity in TMO
Top Purchases
Top Sells
About TMO
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Insider Transactions at TMO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 14
2024
|
Michel Lagarde Executive Vice President & COO |
SELL
Open market or private sale
|
Direct |
20,000
-52.45%
|
$11,800,000
$590.05 P/Share
|
May 14
2024
|
Michel Lagarde Executive Vice President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+34.4%
|
$2,100,000
$105.17 P/Share
|
May 14
2024
|
Stephen Williamson Sr. VP and CFO |
BUY
Bona fide gift
|
Indirect |
12,674
+50.0%
|
-
|
May 14
2024
|
Stephen Williamson Sr. VP and CFO |
SELL
Bona fide gift
|
Direct |
15,971
-23.62%
|
-
|
May 13
2024
|
Stephen Williamson Sr. VP and CFO |
SELL
Open market or private sale
|
Direct |
21,925
-37.54%
|
$12,957,675
$591.27 P/Share
|
May 13
2024
|
Stephen Williamson Sr. VP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,925
+27.29%
|
$4,604,250
$210.68 P/Share
|
May 12
2024
|
Joseph R. Holmes VP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4
-0.22%
|
$2,372
$593.03 P/Share
|
May 05
2024
|
Gianluca Pettiti Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-0.64%
|
$66,924
$572.38 P/Share
|
May 05
2024
|
Frederick M. Lowery Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-1.05%
|
$66,924
$572.38 P/Share
|
May 01
2024
|
Marc N Casper Chairman & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.77%
|
$5,740,000
$574.66 P/Share
|
May 01
2024
|
Marc N Casper Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.95%
|
$1,900,000
$190.59 P/Share
|
Apr 30
2024
|
Marc N Casper Chairman & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.1%
|
$5,720,000
$572.92 P/Share
|
Apr 30
2024
|
Marc N Casper Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.95%
|
$1,900,000
$190.59 P/Share
|
Apr 29
2024
|
Marc N Casper Chairman & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.96%
|
$5,750,000
$575.37 P/Share
|
Apr 29
2024
|
Marc N Casper Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.95%
|
$1,900,000
$190.59 P/Share
|
Apr 26
2024
|
Michael A Boxer SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
2,000
-13.26%
|
$1,134,000
$567.94 P/Share
|
Apr 26
2024
|
Michael A Boxer SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+11.71%
|
$420,000
$210.68 P/Share
|
Mar 25
2024
|
Joseph R. Holmes VP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46
+2.51%
|
-
|
Mar 13
2024
|
Marc N Casper Chairman & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.1%
|
$5,950,000
$595.11 P/Share
|
Mar 13
2024
|
Marc N Casper Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.95%
|
$1,900,000
$190.59 P/Share
|
Last 12 Months Summary
Bona fide gift | 28K shares |
---|---|
Exercise of conversion of derivative security | 258K shares |
Grant, award, or other acquisition | 12.2K shares |
Open market or private purchase | 4 shares |
Payment of exercise price or tax liability | 18.5K shares |
---|---|
Bona fide gift | 33.5K shares |
Open market or private sale | 274K shares |